Tools and Technologies III

Return to Grants

RFA 13-05: CIRM Tools and Technologies III Awards

The CIRM Tools and Technologies initiative intends to support research that can address regenerative medicine’s unique translational challenges. Tools and Technologies III will support the creation, design and testing of broadly applicable novel tools and technologies and the optimization, improvement, standardization or scale-up of existing tools or technologies for addressing translational bottlenecks to stem cell therapies. 

This RFA includes participation by members of CIRM’s Collaborative Funding Partner (CFP) Program.  Appendices A-E describe additional requirements and procedures for applications whose proposals include a request for funding from a CFP.  To assist in the formation of collaborations, CIRM has also provided an online partnering forum as detailed in Appendix F.

Please see the RFA for full details.

RFA 13-05: CIRM Tools and Technologies III Awards [pdf]

Application Process

Submission of an application for this RFA involves a two-step process.  Any eligible applicant may submit a single, brief Preliminary Application (PreApp).   PreApps will be evaluated by scientific specialists from outside California who are experts in specific areas of research described in the PreApp and by CIRM scientific staff, based on the scientific review criteria described in Section IX of the RFA. Applicants submitting the most promising, competitive and responsive PreApp proposals will be invited to submit a detailed, full Application.

Preliminary Application (PreApp) Instructions

PreApps must be submitted online via the CIRM Grants Management Portal at https://grants.cirm.ca.gov/login/upgrade_browser.
Each PI may submit only a single PreApp for this RFA.
The deadline for submission is 5:00 pm (PST) on January 7, 2014. No exceptions to this deadline will be made.

To submit a Preliminary Application:

  1. Go to the Grants Management Portal (https://grants.cirm.ca.gov) and log in with your existing CIRM Username and Password. If you do not have a Username, Click on the “New User” link and follow the instructions to create a CIRM Username and password.
  2. After logging in, Click on the Menu tab. Select the link labeled “Open Programs“. Undert the section labled “RFAs and Programs Open for Applications“, click on the “Start a Preliminary Application” link corresponding to the “RFA 13-05 Tools and Technologies III: Preliminary Application” section.
  3. Using the drop down menu, identify the Institution from which you intend to apply and click “Save“.
  4. Complete each section of the PreApp by clicking on the appropriate link and following the posted instructions. The signature page template (an html print screen) can be found and submitted in the “Upload Required Documents” section.
  5. To submit your PreApp, click on the “Done with Preliminary Application” button. The “Done with Preliminary Application” button will be enabled when all required sections have been completed and the signature page uploaded. Please note that once this has been selected, you will no longer be able to make changes to your PreApp.
  6. To confirm submission of your Preliminary Application, go back to your home page and check the list under the section labeled “Your Submitted Applications“. You will see your PreApp number and project title entered for RFA 13-05 Tools and Technologies III once the submission process has been completed.

Full Application Process

Full Applications will only be accepted from applicants who 1) submitted a PreApp and 2) are invited by CIRM to submit a full application.
The application for the Tools and Techologies III RFA consists of three parts:

Part A: Application Information Form (Web-based form)
Part B: Proposal (MS Word template)
Part C: Biographical Sketches (MS Word template) and Letters of Support

All three parts of the Tools and Technologies III application must be submitted together and received by CIRM no later than 5:00PM PDT on August 11, 2014 via the Grants Management Portal (https://grants.cirm.ca.gov/login/upgrade_browser). It is the applicant’s responsibility to meet this deadline; no exceptions will be made.

Schedule of CIRM Deadlines and Reviews Date
Pre-Applications due 5:00 pm (PST), January 7, 2014
Invitations for Full Applications sent out by CIRM Mid April, 2014
Full Applications due 5:00 pm (PDT), August 11, 2014
Scientific Review of Applications by Grants Working Group (GWG)  November, 2014
Review and Approval by ICOC Winter, 2015
Earliest Funding of Awards Winter/Spring, 2015

No exceptions will be made to the indicated deadlines.

Contact

For information about this RFA or the review process:

Gilberto R. Sambrano, Ph.D.
Associate Director, Review
California Institute for Regenerative Medicine
Email: gsambrano@cirm.ca.gov
Phone: (415) 396-9103
 

ICOC Approval:
January 29, 2015
Total Awards:
22
Award Value:
$29,579,838

Awards

Institution Investigator Grant Title Award Value
University of California, Davis Dr. J. Kent Leach Multi-modal technology for non-destructive characterization of bioengineered tissues $1,574,151
University of Southern California Dr. Qilong Ying Embryonic stem cell-based generation of rat models for assessing human cellular therapies $1,326,979
Stanford University Sarah Heilshorn Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System $1,347,767
Stanford University Dr. James C. Dunn Dr. Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $772,098
University of California, Los Angeles Dr. James C. Dunn Dr. Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $1,044,423
University of California, San Diego Dr. Shyni Varghese Technologies to improve in vivo function of transplanted stem cells $1,373,683
University of California, San Diego Shaochen Chen Development of 3D Bioprinting Techniques using Human Embryonic Stem Cells Derived Cardiomyocytes for Cardiac Tissue Engineering $1,368,264
University of California, Irvine Dr. Mathew Mark Blurton-Jones Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. $1,147,596
University of California, Davis Dr. Laura Marcu Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs $1,834,350
University of Southern California Dr. Paula M. Cannon Site-specific gene editing in hematopoietic stem cells as an anti-HIV therapy $1,495,665
City of Hope, Beckman Research Institute Joseph D Gold Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. $891,518
Stanford University Dr. Fan Yang PhD Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival $1,434,235
University of California, Berkeley Dr. David V. Schaffer Engineered Biomaterials for Scalable Manufacturing and High Viability Implantation of hPSC-Derived Cells to Treat Neurodegenerative Disease $1,239,276
Stanford University Dr. Joseph C. Wu Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts $1,689,744
Stanford University Dr. Anthony E. Oro A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability $1,391,125
University of California, Los Angeles Dr. Hanna Mikkola A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells $1,382,400
University of California, San Francisco Dr. Andrew D. Leavitt MD Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use $1,416,600
Stanford University Professor Irving L Weissman MD Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transp… $1,271,952
University of California, Los Angeles Dr. Carla M. Koehler A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs $1,283,900
University of Southern California Dr. Toshio Miki Development of a clinical-grade extracorporeal liver support system using human induced pluripotent stem cell-derived hepatic cells $1,257,011
Scripps Research Institute Dr. Jeanne F Loring User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery $1,728,390
University of California, Los Angeles Leif Havton Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases $1,308,711
Total:
$29,579,837.86